Safety Assessment Workflow
The Virtual Human Platform uses a generic safety assessment workflow as a five-step process to collect information critical for risk characterisation.
Each step in the generic Safety Assessment Workflow represents a critical process where relevant information is gathered to enable innovative, user-driven risk characterisation. The workflow steps are not strictly sequential. The risk characterisation outcome depends on the specific tools applied, the nature and quality of the information collected, and the way uncertainties are addressed and balanced. The workflow aligns with international concepts, such as the WHO human health risk assessment toolkit and the ASPA workflow. Expand a step below to learn more.
A process flow step that is named after hazard assessment and considered to be cheminformatics-based. It categorizes services that use molecular structures, chemical descriptors, and databases to predict or analyze the properties, behavior, and potential risks of chemical substances.
A process flow step that is named after exposure assessment and categorizes services that evaluate and analyze the route, duration, magnitude and frequency of exposure of an organism or (sub)population to one or multiple chemicals.
A process flow step that is named after toxicokinetics and categorizes services that analyze the kinetics (absorption, distribution, metabolism and excretion) of chemicals and how these processes influence the internal dose. The kinetics step contains four physiological processes substeps: Absorption, Distribution, Metabolism, and Excretion which can be captured in PBK models.
A process flow step that is named after Toxicodynamics and categorizes services that use or extend the (quantitative) AOP framework to analyze and assess the interaction of chemicals with biological targets.
A process flow step that is named after adverse outcome, although specifically refers to clinical and epidemiological effects. It categorizes services that provide information on the toxicological endpoints and adverse outcomes at a clinical or epidemiological level of chemical exposures.